New peptide-based diagnostic and therapeutic approaches hold promise for highly selective targeting of cancer leading to more precise and effective diagnostic and therapeutic modalities. An important feature of these approaches is to reach the tumor tissue while limiting or minimizing the dose to normal organs. In this context, efforts to design and engineer materials with optimal in vivo targeting and clearance properties are important. This Data In Brief article reports on biodistribution and radiation absorbed dose profile of a novel high affinity radiopeptide specific for bone marrow-derived tumor vasculature. Background information on the design, preparation, and in vivo characterization of this peptide-based targeted radiodiagnostic is described in the article "Synthesis and comparative evaluation of novel 64Cu-labeled high affinity cell-specific peptides for positron emission tomography of tumor vasculature" (Merrill et al., 2016) [1]. Here we report biodistribution measurements in mice and calculate the radiation absorbed doses to normal organs using a modified Medical
Internal Radiation Dosimetry (MIRD) methodology that accounts for physical and geometric factors and cross-organ beta doses.
& 2016 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Specifications Table

Subject area
Chemistry in radiology More specific subject area
Materials Science
Type of data Tables  How data was  acquired Direct collection of tissues from mice at different time-points post-injection
Data format
Analyzed data Experimental factors
Novel radiopeptide targeting tumor vasculature was administered intravenously into mice Experimental features
Biodistribution data were analyzed using more precise method accounting for the small size of the murine organs and for the type of radionuclide emissions Data source location USA
Data accessibility
Data is provided within this article
Value of the data
The data reported here demonstrate how mouse tissue distribution measurements can be used to determine radiation absorbed dose to normal mouse tissues and organs.
Using this improved dosimetric approach that incorporates cross-organ beta doses permits refined and more accurate estimates of the radiation absorbed dose to normal tissues.
Accurate absorbed dose estimates which account for the size (mass and dimensions) of the murine organs or lesions as well as for the decay characteristics of the radionuclide are essential in evaluating novel radiodiagnostic and radiotherapeutic compounds.
Cross-organ contributions may be very important for understanding differences in biologic effects in tumors and micro metastasis in different organs.
The data presented here can be of value to material scientists and engineers to more accurately evaluate radiation safety profiles of new radiodiagnostic and radiopharmaceutic compositions in mice.
Data
Previous reports have shown that the high affinity, high specificity FHT-peptide selected by screening of a bacteriophage library [2, 3] , when labeled with the positron emission tomography radionuclide, copper-64, 64 Cu, can specifically image bone marrow-derived tumor vasculature [1, 4] . In this Data in Brief article we provide data on biodistribution of this radiopeptide at 1 h, 4 h, and 24 h post-injection in a subcutaneous Lewis lung carcinoma tumor model (Table 1) . From the biodistribution data, using a geometric model that accounts for the small size of the murine organs [5] and for the decay characteristics of the 64 Cu radionuclide [6] , we have determined the specific accumulated activity in mouse organs over time ( Table 2) and we have calculated radiation absorbed dose in the liver, spleen, kidney, lungs, heart, stomach, small and large intestine, thyroid, pancreas, and murine carcass ( Table 3 ).
Experimental design, materials and methods
The animal protocols were approved by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.
Biodistribution in tumor bearing C57BL/6 mice
Approximately 0.74 MBq of 64 Cu-labeled peptide in a total volume of 150 μl of saline was injected under anesthesia intravenously via a catheter in the tail vein in Lewis lung carcinoma (LLC) tumorbearing C57BL/6 mice (n ¼3 per time point) as described in Ref. [1] . At 1 h, 4 h, or 24 h post-injection mice were sacrificed under anesthesia and liver, spleen, kidney, lungs, heart, stomach, small and large intestines, thyroid, pancreas, and muscle were harvested. The organs were weighted and their radioactivity was measured in an automated gamma counter (WIZARD2, Perkin Elmer Life Sciences, Gaithersburg, MD). Radioactivity concentrations were calibrated, decay-corrected, and expressed as percentage of injected dose per gram tissue (%ID/g). The percentage of injected dose per gram carcass was approximated from radioactivity in a sample of muscle. The biodistribution data at different time points post injection are presented in Table 1 . 
Dosimetry calculations
The method for calculating the dose from internal beta emitters in mice was developed for 90 Y by Hui et al. [5] and extended to other radionuclides, including 64 Cu, by Miller et al. [6] . This method includes cross-organ contributions from beta particles and ignores the dose from photons which are more likely to completely escape the mouse. The absorbed dose, D, to a target organ, k, from a source organ, h, is given by:
where K is a unit conversion constant, E β is the average energy of emitted beta particles (0.121 MeV for 64 Cu), φ β r k 'r h ð Þis the fraction of energy emitted in source organ h that is absorbed in target organ k, A $ h m h is the specific accumulated activity in the source organ h, and m k is the mass of the target organ k. Absorbed fractions in mouse organs for 64 Cu are taken from Ref. [6] .
Accumulated activity is found from the gamma counting biodistribution data collected at 1, 4 and 24 h post-injection converted to specific activity in Bq/g and normalized to an injected dose of 1 MBq. These values are plotted with respect to time of sacrifice to create a time-activity curve and the accumulated activity is found by integrating this curve. Integration was performed by the trapezoidal method up to the 24 h time point. Activity trapped in an organ after 24 h was considered to be cleared only by the physical decay of 64 Cu with a half-life of 12.701 h. The accumulated activity from this period was found by integrating the exponential decay to infinity:
The specific accumulated activity in each organ for each time interval measured and over all time is summarized in Table 2 . The accumulated activity contained in each source organ is found by multiplying the accumulated activity per gram by the average mass of the organ.
The source-to-target doses for each MBq of injected activity are summarized in Table 3 . For each target organ, the total dose is found by summing the contributions from all source organs: The final column of Table 3 displays these total target organ absorbed doses in mGy per MBq of injected activity.
